Organon currently expects that it will record approximately $6 million of milestone expense in the first quarter of 2025. Organon does not forecast IPR&D (in process research and development) or ...

In my work at Organon in counseling my colleagues on various ... I can start my day in Singapore or India and end my day in Brazil or Mexico. It's fascinating, but there's always so much going ...

Pharmaceutical company Organon (NYSE:OGN) reported Q4 CY2024 results , but sales were flat year on year at $1.59 billion. On the other hand, the company’s full-year revenue guidance of $6.23 ...

Organon is broadening its presence in dermatology with a deal to acquire Dermavant, a company whose main asset is a commercialized plaque psoriasis drug that could soon expand its approval to ...

BofA analyst Jason Gerberry lowered the firm’s price target on Organon (OGN) to $10 from $11 and keeps an Underperform rating on the shares. The firm said the company cutting its dividend was a ...

Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue ...

Organon has faced significant price volatility and underperformance since its spin-off from Merck, with shares down ~50% since 2021. Key products like Nexplanon and VTAMA are crucial for future ...

However, Organon was down 1.4%. Sign up here. Dermavant's Vtama cream, approved by the U.S. Food and Drug Administration in May 2022, treats psoriasis, a common long-term inflammatory skin disease.